par Wolking, Stefan;Schulz, Herbert;Nies, Anne A.T.;McCormack, Mark;Schaeffeler, Elke;Auce, Pauls;Avbersek, Andreja;Becker, Felicitas;Klein, Karl Martin;Krenn, Martin;Møller, Rikke Steensbjerre;Nikanorova, Marina;Weckhuysen, Sarah;Consortium, Epi PGx;Cavalleri, Gianpiero;Delanty, Norman;Depondt, Chantal ;Johnson, Michael;Koeleman, B.P.C.;Kunz, Wolfram W.S.;Marson, Anthony Guy;Sander, Josemir W;Sills, Graeme;Striano, Pasquale;Zara, Federico;Zimprich, Fritz;Weber, Yvonne Y.G.;Krause, Roland;Sisodiya, Sanjay;Schwab, Matthias;Sander, Thomas;Lerche, Holger
Référence Pharmacogenomics, 21, 5, page (325-335)
Publication Publié, 2020-04-01
Référence Pharmacogenomics, 21, 5, page (325-335)
Publication Publié, 2020-04-01
Article révisé par les pairs
Résumé : | Aim: Pharmacoresistance is a major burden in epilepsy treatment. We aimed to identify genetic biomarkers in response to specific antiepileptic drugs (AEDs) in genetic generalized epilepsies (GGE). Materials & methods: We conducted a genome-wide association study (GWAS) of 3.3 million autosomal SNPs in 893 European subjects with GGE - responsive or nonresponsive to lamotrigine, levetiracetam and valproic acid. Results: Our GWAS of AED response revealed suggestive evidence for association at 29 genomic loci (p <10-5) but no significant association reflecting its limited power. The suggestive associations highlight candidate genes that are implicated in epileptogenesis and neurodevelopment. Conclusion: This first GWAS of AED response in GGE provides a comprehensive reference of SNP associations for hypothesis-driven candidate gene analyses in upcoming pharmacogenetic studies. |